Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient
- 25 July 2017
- journal article
- Published by BioExcel in Drugs in Context
- Vol. 6, 1-5
- https://doi.org/10.7573/dic.212310
Abstract
Lenvatinib, a multikinase inhibitor, is approved for the treatment of patients with radioiodine-refractory metastatic thyroid cancer on the basis of a Phase III, prospective, double-blind, randomized, placebo-controlled trial that showed longer progression-free survival in the drug-treated arm. Here, we report the case of a young papillary thyroid cancer patient, pretreated with three other kinase inhibitors, who achieved a long-term clinical benefit from lenvatinib in the fourth-line setting.Keywords
This publication has 8 references indexed in Scilit:
- Biologic and Clinical Perspectives on Thyroid CancerThe New England Journal of Medicine, 2016
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Lenvatinib and radioiodine-refractory thyroid cancersNature Reviews Endocrinology, 2015
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid CancerThe New England Journal of Medicine, 2015
- Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF networkActa Endocrinologica, 2014
- The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.Journal of Clinical Endocrinology & Metabolism, 2013
- Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase InhibitorsJournal of Clinical Oncology, 2012
- Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid CarcinomaThyroid®, 2011